A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Targeted Disease(s):
Pulmonary Fibrosis

Purpose of Study:

Treatment

Study Dates:
October 5, 2022 - November 23, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Boehringer Ingelheim

Sponsors:

Boehringer Ingelheim

Contact:

Phone: 1-800-243-0127
Email: clintriage.rdg@boehringer-ingelheim.com

ClinicalTrails.gov Identifier:
NCT05321082

Register for Trial